AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2897812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 266
Study 2897812 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25-50 mg bid)
Number of subjects: 266
Study 2897812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both beta‐adrenoceptor antagonists
Number of subjects: 266
Study 1218150 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mulitre/kg of Althesin for induction of anaesthesia
Number of subjects: 30
Study 1218150 — intervention group
Group type: COMPARATOR
Intervention: 100 mulitre/kg of Althesin for induction of anaesthesia
Number of subjects: 30
Study 31286802 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (anti-PD-L1 antibody)
Number of subjects: 0
Study 31286802 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (as second-line treatment)
Number of subjects: 0
Study 31286802 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (as maintenance therapy)
Number of subjects: 0
Study 31286802 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (in combination with chemotherapy)
Number of subjects: 0
Study 28332720 — intervention group
Group type: EXPERIMENTAL
Intervention: Luliconazole 5% nail solution, applied once daily for 48 weeks
Number of subjects: 293
Study 28332720 — intervention group
Group type: COMPARATOR
Intervention: Vehicle, applied once daily for 48 weeks
Number of subjects: 293
Study 26469083 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based RBV (1,000 or 1,200 mg/day)
Number of subjects: 493
Study 26469083 — intervention group
Group type: COMPARATOR
Intervention: Flat-dose RBV (800 mg/day)
Number of subjects: 493
Study 26469083 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based RBV (≥13 mg/kg/day)
Number of subjects: 493
Study 26469083 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based RBV (<13 mg/kg/day)
Number of subjects: 493
Study 24695944 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0
Study 24695944 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research project
Number of subjects: 0
Study 22050862 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic evaluation with clinical notes
Number of subjects: 51
Study 22050862 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical notes evaluation
Number of subjects: 51
Study 19559401 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 89
Study 19559401 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 89
Study 19559401 — intervention group
Group type: COMPARATOR
Intervention: No-regulation control
Number of subjects: 89
Study 17453398 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 3 times daily for 7 days
Number of subjects: 186
Study 17453398 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib twice daily for 7 days
Number of subjects: 186
Study 17453398 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 7 days
Number of subjects: 186
Study 12967321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 55
Study 12967321 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg)
Number of subjects: 55
Study 12967321 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 55
Study 12967321 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (combined pravastatin and simvastatin)
Number of subjects: 55
Study 12967321 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 55
Study 11523255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) 20 mg per day
Number of subjects: 81
Study 11523255 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 15 mg per week
Number of subjects: 81
Study 11523255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF)
Number of subjects: 81
Study 11523255 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 81
Study 9762745 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic
Number of subjects: 323
Study 9762745 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 323
Study 7937251 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise program of walking and support group meetings
Number of subjects: 14
Study 7937251 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 14
Study 3069466 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200-400 mg twice daily)
Number of subjects: 11
Study 3069466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10-20 mg three times daily)
Number of subjects: 11
Study 3069466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3069466 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol and Nifedipine
Number of subjects: 11
Study 29864071 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) warm‐up program
Number of subjects: 2265
Study 29864071 — intervention group
Group type: COMPARATOR
Intervention: Previous ASI
Number of subjects: 2265
Study 29864071 — intervention group
Group type: COMPARATOR
Intervention: Participation in basketball versus soccer
Number of subjects: 2265
Study 26324401 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide 50 µg once daily
Number of subjects: 0
Study 26324401 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium bromide 18 µg once daily
Number of subjects: 0
Study 24036725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg ion‐incorporated titanium implants
Number of subjects: 114
Study 24036725 — intervention group
Group type: COMPARATOR
Intervention: RBM surface titanium implants
Number of subjects: 114
Study 21235752 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder function training (3 × 20 min sessions with training supervision)
Number of subjects: 100
Study 21235752 — intervention group
Group type: COMPARATOR
Intervention: Advice to stay physically active (Control group)
Number of subjects: 100
Study 18714252 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-glycerol (CG) beverage
Number of subjects: 10
Study 18714252 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (C) beverage
Number of subjects: 10
Study 17961107 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART regimen with two NRTIs (didanosine + stavudine) plus NNRTI (efavirenz)
Number of subjects: 153
Study 17961107 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART regimen with two NRTIs (didanosine + stavudine) plus PI (nelfinavir)
Number of subjects: 153
Study 17961107 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART regimen with two NRTIs (didanosine + stavudine) plus both NNRTI (efavirenz) and PI (nelfinavir)
Number of subjects: 153
Study 17961107 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART regimen with two NRTIs (didanosine + stavudine) plus NNRTI (efavirenz) or PI (nelfinavir)
Number of subjects: 153
Study 17961107 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART regimen with four-drug, three-class regimens
Number of subjects: 153
Study 15047441 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal gymnastics (twice a week, 45 min sessions, 60% of maximum heart frequency)
Number of subjects: 50
Study 15047441 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antenatal gymnastics)
Number of subjects: 50
Study 10742359 — intervention group
Group type: EXPERIMENTAL
Intervention: Encounter-based immunization prompting system
Number of subjects: 0
Study 10742359 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prompting system)
Number of subjects: 0
Study 10742359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-intervention knowledge scores for intervention group
Number of subjects: 0
Study 10742359 — intervention group
Group type: COMPARATOR
Intervention: Pre- and post-intervention knowledge scores for control group
Number of subjects: 0
Study 8732310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100‐300 mg/day)
Number of subjects: 160
Study 8732310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 160
Study 8732310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 1549538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 100 mg
Number of subjects: 14
Study 1549538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg
Number of subjects: 14
Study 1549538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg
Number of subjects: 14
Study 1549538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3886500 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2)
Number of subjects: 20
Study 3886500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31880235 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette message exposure
Number of subjects: 0
Study 31880235 — intervention group
Group type: COMPARATOR
Intervention: Persuasive messages
Number of subjects: 0
Study 30255188 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured rice polyphenol extracts (PE) from purple rice at 10, 20, 50, 100, 200 and 500 μg mL‐1
Number of subjects: 0
Study 30255188 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured rice polyphenol extracts (PE) from red rice at 10, 20, 50, 100, 200 and 500 μg mL‐1
Number of subjects: 0
Study 30255188 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured rice polyphenol extracts (PE) from brown rice at 10, 20, 50, 100, 200 and 500 μg mL‐1
Number of subjects: 0
Study 30255188 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown rice PE at 50 μg mL‐1
Number of subjects: 0
Study 30255188 — intervention group
Group type: EXPERIMENTAL
Intervention: Red rice PE at 50 μg mL‐1
Number of subjects: 0
Study 30255188 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple rice PE at 50 μg mL‐1
Number of subjects: 0
Study 30255188 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured rice polyphenol extracts (PE)
Number of subjects: 0
Study 27521719 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 SQ HDM SLIT-tablet
Number of subjects: 1482
Study 24798210 — intervention group
Group type: EXPERIMENTAL
Intervention: West Wales ADR Profile for Respiratory Medicine
Number of subjects: 54
Study 24798210 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study 22486815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 131
Study 22486815 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 131
Study 20169656 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal treatment including endoscopic haemostatic and high-dose intravenous proton-pump inhibitors
Number of subjects: 140
Study 18571502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg/day)
Number of subjects: 40
Study 18571502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16100643 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp excision of endometriosis
Number of subjects: 29
Study 16100643 — intervention group
Group type: COMPARATOR
Intervention: Sham surgical excision (control)
Number of subjects: 29
Study 12367547 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (topical anaesthetic)
Number of subjects: 56
Study 12367547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 10602525 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI evidence of cord edema
Number of subjects: 499
Study 10602525 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hemorrhage
Number of subjects: 499
Study 10602525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord hemorrhage, contusion, and edema on MRI
Number of subjects: 499
Study 8952311 — intervention group
Group type: EXPERIMENTAL
Intervention: ARX model
Number of subjects: 10
Study 8952311 — intervention group
Group type: COMPARATOR
Intervention: MTA model
Number of subjects: 10
Study 2009042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with elbow in 90 degree flexion
Number of subjects: 61
Study 2009042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with elbow in full extension
Number of subjects: 61
Study 2009042 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing with elbow in 90 degree flexion
Number of subjects: 61
Study 2009042 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing with elbow in full extension
Number of subjects: 61
Study 2009042 — intervention group
Group type: EXPERIMENTAL
Intervention: Males (all positions)
Number of subjects: 61
Study 7087973 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM extract
Number of subjects: 32
Study 7087973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30871542 — intervention group
Group type: COMPARATOR
Intervention: 1000 IU/day of vitamin D
Number of subjects: 50
Study 30871542 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/day of vitamin D
Number of subjects: 50
Study 30397709 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Cycle
Number of subjects: 332
Study 30397709 — intervention group
Group type: COMPARATOR
Intervention: HRT Cycle
Number of subjects: 332
Study 26970946 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia treatment
Number of subjects: 23
Study 26970946 — intervention group
Group type: COMPARATOR
Intervention: No therapeutic hypothermia treatment (control)
Number of subjects: 23
Study 25252624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα polymorphism "‐1031"
Number of subjects: 542
Study 25252624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα polymorphism "‐863"
Number of subjects: 542
Study 25252624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα G‐A‐G haplotype
Number of subjects: 542
Study 25252624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα "‐1031" minor allele
Number of subjects: 542
Study 25252624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα "‐863" minor allele
Number of subjects: 542
Study 25252624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα "‐1031" and IL4R Ser503Pro interaction
Number of subjects: 542
Study 25252624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα "‐1031" and IL10 "‐1082" interaction
Number of subjects: 542
Study 25252624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα "‐863" and IL10 "‐1082" interaction
Number of subjects: 542
Study 22537984 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg Sanofi-Pasteur vaccine
Number of subjects: 0
Study 22537984 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg CSL vaccine
Number of subjects: 0
Study 22537984 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg dosage
Number of subjects: 0
Study 20231231 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 2701
Study 20231231 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2701
Study 17686209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 0
Study 17686209 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 15 mg/kg
Number of subjects: 0
Study 16330788 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus 5 to 7 plasma exchanges of 50 mL per kg of body weight of 5% human serum albumin for 10 days
Number of subjects: 104
Study 16330788 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 104
Study 11974556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day 17 beta-estradiol combined with 5 or 10 mg/day dydrogesterone
Number of subjects: 579
Study 11974556 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day 17 beta-estradiol combined with 10 or 20 mg/day dydrogesterone
Number of subjects: 579
Study 11974556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day 17 beta-estradiol
Number of subjects: 579
Study 11974556 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of dydrogesterone
Number of subjects: 579
Study 11974556 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (irrespective of estradiol or dydrogesterone dose)
Number of subjects: 579
Study 11974556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579
Study 9952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.075 mg
Number of subjects: 108
Study 9952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.5 mg
Number of subjects: 108
Study 9952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (various doses)
Number of subjects: 108
Study 9952150 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.0 mg intrathecal morphine)
Number of subjects: 108
Study 9952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.0-0.5 mg)
Number of subjects: 108
Study 7567589 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% tilt biphasic pulse
Number of subjects: 15
Study 7567589 — intervention group
Group type: COMPARATOR
Intervention: 50% tilt biphasic pulse
Number of subjects: 15
Study 2190015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT) + Clindamycin (CLDM)
Number of subjects: 160
Study 2190015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (AMK) + Aztreonam (AZT)
Number of subjects: 160
Study 2190015 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (CLDM) + Amikacin (AMK)
Number of subjects: 160
Study 2190015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT) + Clindamycin (CLDM) in patients with neutrophil counts < 500/microliters
Number of subjects: 160
Study 2190015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (AMK) + Aztreonam (AZT) in patients with neutrophil counts < 500/microliters
Number of subjects: 160
Study 2190015 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (CLDM) + Amikacin (AMK) in patients with neutrophil counts < 500/microliters
Number of subjects: 160
Study 859123 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 249
Study 859123 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 249
Study 859123 — intervention group
Group type: EXPERIMENTAL
Intervention: Bourbon
Number of subjects: 249
Study 859123 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft drinks
Number of subjects: 249
Study 30856182 — intervention group
Group type: EXPERIMENTAL
Intervention: siPRBCs (stored for over 21 days)
Number of subjects: 19
Study 30856182 — intervention group
Group type: COMPARATOR
Intervention: fPRBCs (stored for less than 14 days)
Number of subjects: 19
Study 28646901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe add-on therapy (10 mg)
Number of subjects: 109
Study 28646901 — intervention group
Group type: COMPARATOR
Intervention: Double-dose statin therapy
Number of subjects: 109
Study 25636992 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial body weight supported treadmill training
Number of subjects: 30
Study 25636992 — intervention group
Group type: COMPARATOR
Intervention: Over ground walking (control)
Number of subjects: 30
Study 23292315 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficient (serum 25(OH)D ≤32 ng/mL)
Number of subjects: 28
Study 23292315 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D sufficient (serum 25(OH)D >32 ng/mL)
Number of subjects: 28
Study 22286627 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated wrist evaluation (PRWE) questionnaire
Number of subjects: 64
Study 22286627 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength measurement
Number of subjects: 64
Study 19672935 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400 microg daily)
Number of subjects: 133
Study 19672935 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-MTHF (daily)
Number of subjects: 133
Study 19672935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 17082284 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent articaine hydrochloride with 1:200,000 epinephrine (A200)
Number of subjects: 126
Study 17082284 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent articaine hydrochloride with 1:100,000 epinephrine (A100)
Number of subjects: 126
Study 17082284 — intervention group
Group type: COMPARATOR
Intervention: 4 percent articaine hydrochloride without epinephrine (Aw/o)
Number of subjects: 126
Study 15047680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (515 mg/day)
Number of subjects: 160
Study 15047680 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant mixture (515 mg vitamin C, 371 mg alpha-tocopherol, 171 mg gamma-tocopherol, 252 mg mixed tocotrienols, and 95 mg alpha-lipoic acid)
Number of subjects: 160
Study 15047680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 12228852 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (angiotensin receptor blocker)
Number of subjects: 0
Study 12228852 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta-blocker)
Number of subjects: 0
Study 9688035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive neck/shoulder training programme
Number of subjects: 77
Study 9688035 — intervention group
Group type: COMPARATOR
Intervention: Lighter intensity neck/shoulder training programme
Number of subjects: 77
Study 8135388 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium, 0.5 mg/kg
Number of subjects: 20
Study 8135388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium, 0.1 mg/kg
Number of subjects: 20
Study 2800992 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin, 0.8 mg/kg i.v. preoperatively, followed by 100 mg rectally 8-hourly for 3 days
Number of subjects: 41
Study 2800992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2800992 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 41
Study 578400 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 1% solution
Number of subjects: 80
Study 578400 — intervention group
Group type: COMPARATOR
Intervention: Haloprogin 1% solution
Number of subjects: 80
Study 31494820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 46